LEMBOREXANT TREATMENT FOR INSOMNIA: 6-MONTH SAFETY

被引：0
|
作者：
Karppa, Mikko [1 ]
Moline, Margaret [2 ]
Yardley, Jane [3 ]
Pinner, Kate [3 ]
Perdomo, Carlos [2 ]
Filippov, Gleb [2 ]
Zammit, Gary [4 ]
机构：
[1] Univ Oulu, Oulu, Finland
[2] Eisai Inc, Woodcliff Lake, NJ USA
[3] Eisai Ltd, Hatfield, Herts, England
[4] Clinilabs Drug Dev Corp, New York, NY USA
来源：
SLEEP | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
0367
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review
    Ume Habiba
    Radeyah Waseem
    Taha Gul Shaikh
    Summaiyya Waseem
    Syed Hassan Ahmed
    Muhammad Sohaib Asghar
    Neurological Sciences, 2023, 44 : 1533 - 1541
  • [22] Safety of Lemborexant in Elderly Subjects with Insomnia: Results from SUNRISE 1
    Rosenberg, R.
    Filippov, G.
    LoPresti, A.
    Kumar, D.
    Moline, M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 : S218 - S218
  • [23] LONG-TERM EFFECT OF LEMBOREXANT ON FATIGUE IN SUBJECTS WITH INSOMNIA DISORDER: PATIENT-REPORTED OUTCOME FROM THE 6-MONTH PLACEBO-CONTROLLED TREATMENT PERIOD OF THE PHASE 3 STUDY SUNRISE-2
    Yardley, J.
    Moline, M.
    Pinner, K.
    Perdomo, C.
    Fillipov, G.
    Karppa, M.
    SLEEP MEDICINE, 2019, 64 : S264 - S264
  • [24] Comparative efficacy and safety of lemborexant 5 mg versus 10 mg for the treatment of insomnia: a systematic review
    Habiba, Ume
    Waseem, Radeyah
    Shaikh, Taha Gul
    Waseem, Summaiyya
    Ahmed, Syed Hassan
    Asghar, Muhammad Sohaib
    NEUROLOGICAL SCIENCES, 2023, 44 (05) : 1533 - 1541
  • [25] SHIFTS IN DAYTIME FUNCTIONING ITEMS ON THE INSOMNIA SEVERITY SCALE WITH LEMBOREXANT AFTER 6 MONTHS OF TREATMENT
    Chepke, Craig
    Cote, Kimberly
    Pinner, Kate
    Yardley, Jane
    Moline, Margaret
    SLEEP, 2023, 46
  • [26] Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder
    Waters, Kristin
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (02) : 213 - 221
  • [27] LAMOTRIGINE - A 6-MONTH, PLACEBO-CONTROLLED, SAFETY AND TOLERANCE STUDY
    SCHACHTER, SC
    LEPPIK, IE
    MATSUO, F
    MESSENHEIMER, J
    FAUGHT, E
    MOORE, EL
    RISNER, ME
    JOURNAL OF EPILEPSY, 1995, 8 (03): : 201 - 209
  • [28] The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
    Eric J. Shiuey
    Nikki A. Mehran
    Melih Ustaoglu
    Qiang Zhang
    Reza Razeghinejad
    Aakriti G. Shukla
    Natasha N. Kolomeyer
    Jonathan S. Myers
    Daniel Lee
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 967 - 974
  • [29] CIMETIDINE, RANITIDINE, AND PIRENZEPINE IN THE TREATMENT OF DUODENAL-ULCER - A 6-MONTH LOW-DOSE TREATMENT PERIOD FOLLOWED BY A 6-MONTH OBSERVATION PERIOD
    LEANDRO, G
    BATTAGLIA, G
    DIMARIO, F
    COZZOLONGO, R
    GIANNUZZI, V
    CANNIZZARO, R
    MANGHISI, OG
    NACCARATO, R
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1990, 47 (01): : 218 - 225
  • [30] The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
    Shiuey, Eric J.
    Mehran, Nikki A.
    Ustaoglu, Melih
    Zhang, Qiang
    Razeghinejad, Reza
    Shukla, Aakriti G.
    Kolomeyer, Natasha N.
    Myers, Jonathan S.
    Lee, Daniel
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (03) : 967 - 974
12345